Ozempic Back in the News for all the Wrong Reasons
The latest news is that the much hyped weight loss drugs cause NAION, or non-arteritic anterior ischemic optic neuropathy.
In 2018, the European Union approved Ozempic, an injectable medication containing semaglutide, for patients with type 2 diabetes. This approval did not extend to weight management. In 2022, a weight-…
